Sugi Predict

Sugi Predict / Compounds / SCHEMBL1352602

SCHEMBL1352602

SCHEMBL1352602

O=C(O)c1cnc2cc(Br)ccc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGAM O43451 1/20 0.62
▸ POLB P06746 1/20 0.46
▸ HCAR2 Q8TDS4 1/20 0.46
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ HPGDS O60760 5/20 0.44
▸ PSMD14 O00487 1/20 0.43
▸ MMP2 P08253 1/20 0.42
▸ MMP9 P14780 1/20 0.42
▸ MMP8 P22894 1/20 0.42
▸ MMP13 P45452 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ ALPL P05186 1/20 0.41
▸ EGLN1 Q9GZT9 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ P4HA1 P13674 1/20 0.40
▸ P4HTM Q9NXG6 1/20 0.40
▸ CFTR P13569 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9508 0.86 MGAM (0.62) MGAMPOLBHCAR2HTTPSMD14
SCHEMBL4541927 0.85 HPGDS (0.61) MGAMCYP1A2CYP2C19HTTHPGDS
SCHEMBL7601178 0.85 HPGDS (0.47) MGAMCYP1A2CYP2C19HTTHPGDS
SCHEMBL69368 0.84 MGAM (0.68) MGAMCYP1A2CYP2C19HPGDSPSMD14
SCHEMBL7600509 0.82 GSK3B (0.49) MGAMCYP1A2CYP2C19HTTHPGDS
SCHEMBL2001821 0.81 HPGDS (0.51) HTTHPGDSPSMD14MMP2MMP9
SCHEMBL1353291 0.81 MGAM (0.64) MGAMHPGDSPSMD14ALDH1A1P4HA1
SCHEMBL14215687 0.80 HPGDS (0.45) MGAMCYP1A2CYP2C19HTTHPGDS
SCHEMBL4158038 0.79 MGAM (0.62) MGAMHCAR2HPGDSPSMD14EGLN1
SCHEMBL6769263 0.79 MGAM (0.62) MGAMPOLBHTTHPGDSPSMD14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119661553-A Brucea javanica kurol quinoline derivative and preparation method and application thereof 中国人民解放军西部战区总医院 2025-03-21 — — CN disclosed
US-20220315565-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FORMA THERAPEUTICS, INC. 2022-10-06 — — US disclosed
US-11299484-B2 Inhibiting fatty acid synthase (FASN) FORMA THERAPEUTICS, INC. (US) 2022-04-12 — — US disclosed
EP-3565807-B1 OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS ICAHN SCHOOL MED MOUNT SINAI (US) 2021-09-22 — — EP disclosed
EP-3390384-B1 QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2021-09-15 — — EP disclosed
CN-113329748-A Inhibition of Fatty Acid Synthase (FASN) 福马治疗股份有限公司 2021-08-31 — — CN disclosed
US-20210238162-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-08-05 — — US disclosed
US-20210024508-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FORMA THERAPEUTICS, INC. 2021-01-28 — — US disclosed
US-10875848-B2 Inhibiting fatty acid synthase (FASN) FORMA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
EP-3753932-A1 SUBSTITUTED BICYCLIC DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2020-12-23 — — EP disclosed
US-20120122864-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2012-05-17 — — US disclosed
US-20120122864-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2012-05-17 — — US disclosed
WO-2011149856-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2011-12-01 — — WO disclosed
US-20110288117-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-11-24 — — US disclosed
WO-2011146591-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-11-24 — — WO disclosed
WO-2010065674-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2010-06-10 — — WO disclosed
US-7511145-B2 Bicyclic heteroaryl derivatives GENELABS TECHNOLOGIES, INC. (US) 2009-03-31 — — US disclosed
US-7511145-B2 Bicyclic heteroaryl derivatives GENELABS TECHNOLOGIES, INC. (US) 2009-03-31 — — US disclosed
US-20090081165-A1 BICYCLIC HETEROARYL DERIVATIVES GENELABS TECHNOLOGIES, INC. 2009-03-26 — — US disclosed
US-20090081165-A1 BICYCLIC HETEROARYL DERIVATIVES GENELABS TECHNOLOGIES, INC. 2009-03-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10875848-B2 Inhibiting fatty acid synthase (FASN) FASN, SCD, FADS1 MGAM 1662/4885POLB 1211/4885HCAR2 754/4885
US-20090081165-A1 BICYCLIC HETEROARYL DERIVATIVES HAVCR2, MAVS, ZC3HAV1 MGAM 2546/4885POLB 870/4885HCAR2 3754/4885
US-20210024508-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FASN, SCD, FADS1 MGAM 1662/4885POLB 1211/4885HCAR2 754/4885
US-20120122864-A1 INHIBITORS OF HCV NS5A HAVCR2, MAVS, EIF2AK2 MGAM 4158/4885POLB 1454/4885HCAR2 4754/4885
US-20110288117-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC5 MGAM 4458/4885POLB 438/4885HCAR2 23/4885
US-20210238162-A1 CHEMICAL COMPOUNDS HPGDS, PTGS1, PTGIS MGAM 3150/4885POLB 1288/4885HCAR2 600/4885
US-20220315565-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FASN, SCD, FADS1 MGAM 1662/4885POLB 1211/4885HCAR2 754/4885
US-11299484-B2 Inhibiting fatty acid synthase (FASN) FASN, SCD, FADS1 MGAM 1662/4885POLB 1211/4885HCAR2 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.